Today on Drug Discovery & Development
Columbia-CZ team develops 10.3M parameter model that outperforms 100M parameter rivals on cell type classification
A new foundation model called GREmLN from a Columbia and Chan Zuckerberg Biohub team, delivers superior cell-type classification with only 10.3 million parameters, outpacing rivals like the 100-million-parameter scFoundation. Released July 9 on bioRxiv, it taps gene regulatory networks to achieve a 0.929 macro F1 score on immune cell data. “Instead of using large language…
New treatment paradigms in oncology: Highlights from the ASCO 2025 annual meeting
As in previous years, the 2025 ASCO Annual Meeting showcased a strong portfolio of practice-changing data across a wide range of tumor types. Combination therapies remain a central theme, continuing to drive meaningful improvements in clinical outcomes. These benefits are increasingly balanced by evolving strategies for managing adverse events, underscoring the field’s commitment to both…
Drug Discovery and Development See More >
Columbia-CZ team develops 10.3M parameter model that outperforms 100M parameter rivals on cell type classification
A new foundation model called GREmLN from a Columbia and Chan Zuckerberg Biohub team, delivers superior cell-type classification with only 10.3 million parameters, outpacing rivals like the 100-million-parameter scFoundation. Released July 9 on bioRxiv, it taps gene regulatory networks to achieve a 0.929 macro F1 score on immune cell data. “Instead of using large language…
Sponsored Content See More >
Complexity’s counterpoint: Understanding protocol optimization In recent years, the clinical research landscape has been marked by a steady rise in protocol complexity with more endpoints…
Optimizing Data Pipelines in Life Sciences with AI-Driven Integration and FHIRSponsored by Infor. Data management in life sciences is inherently complex. Data is fragmented across multiple systems — such…
Accelerating life sciences with AI This case study is sponsored by Infor. Artificial intelligence can revolutionize clinical interoperability by building bridges across data silos. Machine…
Advancing Clinical Trials and ResearchThis case study is sponsored by Infor. In the complex landscape of clinical trials and medical research, data fragmentation remains…
Multidisciplinary approaches optimize contract drug discovery
5 Key Questions in Conducting Global Usability StudiesBy Dr Bryce G Rutter, Head Noble Consulting Services Evaluating device usability throughout the product development process is crucial. A…
Leveraging HF/UX/ID Services to Optimize the Design of Combination Devices for Arthritic HandsBy Dr. Bryce G Rutter, Head of Consulting Services Arthritis changes how people grasp and manipulate an object, reducing the…
Ask the Expert: Navigating the New FDA Rules on Laboratory Developed Tests (LDTs)The U.S. FDA released a final rule to regulate laboratory developed tests (LDTs) on May 6, 2024, making it clear…
How tailored qPCR assays can unlock microbiome and precision medicine potential Sponsored by Diversigen, Inc. Quantitative Polymerase Chain Reaction (qPCR) — also known as real-time PCR — is a molecular…
Innovations in Baculovirus–Insect Cell Expression SystemsThe baculovirus–insect cell expression system—insect cells used in conjunction with the baculovirus expression vector system (BEVS)—remains a crucial technology for…
Patient Training is Broken – And Everyone is Paying For ItNoble International is working with Pharma and Specialty Pharmacy to fix the problem. The report, “The Current Paradigm for Biologic…
Noble Leads with its User-Centered Design StrategyBy Tim McLeroy, Executive Director of Marketing and Patient Services, Noble International At Noble, the patient journey drives everything we…
Genomics/Proteomics See More >
Columbia-CZ team develops 10.3M parameter model that outperforms 100M parameter rivals on cell type classification
A new foundation model called GREmLN from a Columbia and Chan Zuckerberg Biohub team, delivers superior cell-type classification with only 10.3 million parameters, outpacing rivals like the 100-million-parameter scFoundation. Released July 9 on bioRxiv, it taps gene regulatory networks to achieve a 0.929 macro F1 score on immune cell data. “Instead of using large language…
Spatial biology: Transforming our understanding of cellular environments
Biotech in 2025: Precision medicine, smarter investments, and more emphasis on RWD in clinical trials
Genomics in 2025: How $500 whole genome sequencing could democratize genomic data
St. Jude pioneers gene editing and structural biology to advance pediatric research
Infectious Disease See More >
Six leading medical organizations sue RFK Jr. over vaccine recommendations
Several leading medical organizations filed a lawsuit against Robert F. Kennedy Jr. on Monday, claiming that recent decisions to stop recommending vaccines to pregnant women and children are unscientific and harmful to the public. The suit was filed in the U.S. District Court for the District of Massachusetts. The American Public Health Association (APHA), the…
RFK’s new ACIP changed longstanding vaccine recommendations
Secretary of Health removes all current members of the CDC advisory committee on immunization practices
FDA COVID booster pullback jolts vaccine stocks before gains cool
Pregnancy associated with less long COVID: Researchers call for studies on protective biology
Oncology See More >
New treatment paradigms in oncology: Highlights from the ASCO 2025 annual meeting
As in previous years, the 2025 ASCO Annual Meeting showcased a strong portfolio of practice-changing data across a wide range of tumor types. Combination therapies remain a central theme, continuing to drive meaningful improvements in clinical outcomes. These benefits are increasingly balanced by evolving strategies for managing adverse events, underscoring the field’s commitment to both…
Korean team reports all-in-one cancer nanomedicine in pre-clinical studies
As some biotechs cut, Genmab unveils striking new site near Princeton
OS Therapies announces favorable FDA feedback on external control arm strategy for osteosarcoma drug
